drugset / Trial / NCT02264041

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

NCT02264041

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the effect of cytochrome P 450 3A4 inhibition by itraconazole on the single dose pharmacokinetics of cilobradine

Timeline

Start
2004-01
Primary completion
2004-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilobradine Small molecule
Subject Itraconazole Small molecule

Indications

No indication recorded.